{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:15:57Z","timestamp":1791951357803,"version":"4.3.4"},"reference-count":195,"publisher":"BMJ","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Despite considerable advances in treatment approaches in the past two decades, multiple myeloma remains an incurable disease. Treatments for myeloma continue to evolve with many emerging immunotherapies. The first immunotherapy used to treat hematologic cancers, including multiple myeloma, was an allogeneic stem cell transplant. In the mid-2000s, immunomodulatory drugs thalidomide, lenalidomide, and subsequently pomalidomide were proven to be effective in multiple myeloma and substantially improved survival. The next wave of immunotherapies for multiple myeloma included the monoclonal antibodies daratumumab and elotuzumab, which were approved by the Food and Drug Administration in 2015. Subsequently, a variety of immunotherapies have been developed for multiple myeloma, including chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates, and checkpoint inhibitors. Many of these emerging treatments target the B cell maturation antigen, which is expressed on plasma cells, although several other novel receptors are also being studied. This review summarizes the evidence of these various immunotherapies, their mechanism of action, and data from clinical trials regarding the treatments\u2019 safety and efficacy.<\/jats:p>","DOI":"10.1136\/bmj.m3176","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T12:54:27Z","timestamp":1600692867000},"page":"m3176","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":124,"title":["Emerging immunotherapies in multiple myeloma"],"prefix":"10.1136","author":[{"given":"Urvi A","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"key":"2020092107450524000_370.sep21_2.m3176.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"2020092107450524000_370.sep21_2.m3176.2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2111"},{"key":"2020092107450524000_370.sep21_2.m3176.3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004"},{"key":"2020092107450524000_370.sep21_2.m3176.4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2128"},{"key":"2020092107450524000_370.sep21_2.m3176.5","doi-asserted-by":"crossref","unstructured":"Ganguly S Mailankody S Ailawadhi S . Many shades of disparities in myeloma care. 2019;519-29.","DOI":"10.1200\/EDBK_238551"},{"key":"2020092107450524000_370.sep21_2.m3176.6","unstructured":"Howlader NA, Noone AM, Krapcho M, et al, (eds). SEER cancer statistics review, 1975-2017, National Cancer Institute. Bethesda, MD. 2020. https:\/\/seer.cancer.gov\/csr\/1975_2017\/."},{"key":"2020092107450524000_370.sep21_2.m3176.7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32802"},{"key":"2020092107450524000_370.sep21_2.m3176.8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"2020092107450524000_370.sep21_2.m3176.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"2020092107450524000_370.sep21_2.m3176.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.11.018"},{"key":"2020092107450524000_370.sep21_2.m3176.11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.200881"},{"key":"2020092107450524000_370.sep21_2.m3176.12","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.325"},{"key":"2020092107450524000_370.sep21_2.m3176.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.03.002"},{"key":"2020092107450524000_370.sep21_2.m3176.14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0689-1"},{"key":"2020092107450524000_370.sep21_2.m3176.15","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718775629"},{"key":"2020092107450524000_370.sep21_2.m3176.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"2020092107450524000_370.sep21_2.m3176.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"2020092107450524000_370.sep21_2.m3176.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"2020092107450524000_370.sep21_2.m3176.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"2020092107450524000_370.sep21_2.m3176.20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14549"},{"key":"2020092107450524000_370.sep21_2.m3176.21","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.31"},{"key":"2020092107450524000_370.sep21_2.m3176.22","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0583-7"},{"key":"2020092107450524000_370.sep21_2.m3176.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"2020092107450524000_370.sep21_2.m3176.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"2020092107450524000_370.sep21_2.m3176.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"2020092107450524000_370.sep21_2.m3176.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"2020092107450524000_370.sep21_2.m3176.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402888"},{"key":"2020092107450524000_370.sep21_2.m3176.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"2020092107450524000_370.sep21_2.m3176.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"2020092107450524000_370.sep21_2.m3176.30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01740"},{"key":"2020092107450524000_370.sep21_2.m3176.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300439"},{"key":"2020092107450524000_370.sep21_2.m3176.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0620-8"},{"key":"2020092107450524000_370.sep21_2.m3176.33","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2019.37.15_suppl.8006","article-title":"First clinical (phase 1b\/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"37","author":"Lonial","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020092107450524000_370.sep21_2.m3176.34","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2020.38.15_suppl.8500","article-title":"First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Richardson","year":"2020","journal-title":"J Clin Oncol"},{"key":"2020092107450524000_370.sep21_2.m3176.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2020.03.010","article-title":"Evolving role of daratumumab: from backbencher to frontline agent","author":"Jain","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2020092107450524000_370.sep21_2.m3176.36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"2020092107450524000_370.sep21_2.m3176.37","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12532"},{"key":"2020092107450524000_370.sep21_2.m3176.38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501351"},{"key":"2020092107450524000_370.sep21_2.m3176.39","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.240"},{"key":"2020092107450524000_370.sep21_2.m3176.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"2020092107450524000_370.sep21_2.m3176.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"2020092107450524000_370.sep21_2.m3176.42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-705210"},{"key":"2020092107450524000_370.sep21_2.m3176.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"2020092107450524000_370.sep21_2.m3176.44","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194118"},{"key":"2020092107450524000_370.sep21_2.m3176.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"2020092107450524000_370.sep21_2.m3176.46","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194282"},{"key":"2020092107450524000_370.sep21_2.m3176.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0711-6"},{"key":"2020092107450524000_370.sep21_2.m3176.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"2020092107450524000_370.sep21_2.m3176.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"2020092107450524000_370.sep21_2.m3176.50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32956-3"},{"key":"2020092107450524000_370.sep21_2.m3176.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"2020092107450524000_370.sep21_2.m3176.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"2020092107450524000_370.sep21_2.m3176.53","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"2020092107450524000_370.sep21_2.m3176.54","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30070-3"},{"key":"2020092107450524000_370.sep21_2.m3176.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"2020092107450524000_370.sep21_2.m3176.56","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31680"},{"key":"2020092107450524000_370.sep21_2.m3176.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"2020092107450524000_370.sep21_2.m3176.58","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1200\/JCO.2020.38.15_suppl.8507","article-title":"Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with\/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211)","volume":"38","author":"Usmani","year":"2020","journal-title":"J Clin Oncol"},{"key":"2020092107450524000_370.sep21_2.m3176.59","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"2020092107450524000_370.sep21_2.m3176.60","doi-asserted-by":"crossref","unstructured":"Moreau P Dimopoulos MA Mikhael J . Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma (Ikema): interim analysis of a phase 3, randomized, open-label study. European Hematology Association 2020.","DOI":"10.2217\/fon-2019-0431"},{"key":"2020092107450524000_370.sep21_2.m3176.61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"2020092107450524000_370.sep21_2.m3176.62","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0813-1"},{"key":"2020092107450524000_370.sep21_2.m3176.63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360552"},{"key":"2020092107450524000_370.sep21_2.m3176.64","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14787"},{"key":"2020092107450524000_370.sep21_2.m3176.65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740787"},{"key":"2020092107450524000_370.sep21_2.m3176.66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-02-895193"},{"key":"2020092107450524000_370.sep21_2.m3176.67","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0616"},{"key":"2020092107450524000_370.sep21_2.m3176.68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051482"},{"key":"2020092107450524000_370.sep21_2.m3176.69","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"2020092107450524000_370.sep21_2.m3176.70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"2020092107450524000_370.sep21_2.m3176.71","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1320713"},{"key":"2020092107450524000_370.sep21_2.m3176.72","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0200"},{"key":"2020092107450524000_370.sep21_2.m3176.73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-775122"},{"key":"2020092107450524000_370.sep21_2.m3176.74","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15946"},{"key":"2020092107450524000_370.sep21_2.m3176.75","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30110-3"},{"key":"2020092107450524000_370.sep21_2.m3176.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.07.142"},{"key":"2020092107450524000_370.sep21_2.m3176.77","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30109-7"},{"key":"2020092107450524000_370.sep21_2.m3176.78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1803602"},{"key":"2020092107450524000_370.sep21_2.m3176.79","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.27"},{"key":"2020092107450524000_370.sep21_2.m3176.80","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1393668"},{"key":"2020092107450524000_370.sep21_2.m3176.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101141"},{"key":"2020092107450524000_370.sep21_2.m3176.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2016.12.006"},{"key":"2020092107450524000_370.sep21_2.m3176.83","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-03592-9"},{"key":"2020092107450524000_370.sep21_2.m3176.84","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.2604"},{"key":"2020092107450524000_370.sep21_2.m3176.85","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.11"},{"key":"2020092107450524000_370.sep21_2.m3176.86","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000379"},{"key":"2020092107450524000_370.sep21_2.m3176.87","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"2020092107450524000_370.sep21_2.m3176.88","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330"},{"key":"2020092107450524000_370.sep21_2.m3176.89","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200318025"},{"key":"2020092107450524000_370.sep21_2.m3176.90","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.3"},{"key":"2020092107450524000_370.sep21_2.m3176.91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821"},{"key":"2020092107450524000_370.sep21_2.m3176.92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2020092107450524000_370.sep21_2.m3176.93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2020092107450524000_370.sep21_2.m3176.94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2020092107450524000_370.sep21_2.m3176.95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903"},{"key":"2020092107450524000_370.sep21_2.m3176.96","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084"},{"key":"2020092107450524000_370.sep21_2.m3176.97","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397"},{"key":"2020092107450524000_370.sep21_2.m3176.98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119717"},{"key":"2020092107450524000_370.sep21_2.m3176.99","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2020.38.15_suppl.8503","article-title":"Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results","volume":"38","author":"Munshi","year":"2020","journal-title":"J Clin Oncol"},{"key":"2020092107450524000_370.sep21_2.m3176.100","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113548"},{"key":"2020092107450524000_370.sep21_2.m3176.101","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J Clin Oncol"},{"key":"2020092107450524000_370.sep21_2.m3176.102","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116"},{"key":"2020092107450524000_370.sep21_2.m3176.103","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"2020092107450524000_370.sep21_2.m3176.104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110548"},{"key":"2020092107450524000_370.sep21_2.m3176.105","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000172"},{"key":"2020092107450524000_370.sep21_2.m3176.106","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001843"},{"key":"2020092107450524000_370.sep21_2.m3176.107","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1200\/JCO.2020.38.15_suppl.8505","article-title":"Update of CARTITUDE-1: A phase Ib\/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed\/refractory multiple myeloma","volume":"38","author":"Berdeja","year":"2020","journal-title":"J Clin Oncol"},{"key":"2020092107450524000_370.sep21_2.m3176.108","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111419"},{"key":"2020092107450524000_370.sep21_2.m3176.109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02657"},{"key":"2020092107450524000_370.sep21_2.m3176.110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122895"},{"key":"2020092107450524000_370.sep21_2.m3176.111","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1200\/JCO.2020.38.15_suppl.100","article-title":"Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed\/refractory multiple myeloma (R\/R MM)","volume":"38","author":"Usmani","year":"2020","journal-title":"J Clin Oncol"},{"key":"2020092107450524000_370.sep21_2.m3176.112","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"2020092107450524000_370.sep21_2.m3176.113","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1200\/JCO.2020.38.15_suppl.8502","article-title":"DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib\/dexamethasone in relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Nooka","year":"2020","journal-title":"J Clin Oncol"},{"key":"2020092107450524000_370.sep21_2.m3176.114","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.001"},{"key":"2020092107450524000_370.sep21_2.m3176.115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"2020092107450524000_370.sep21_2.m3176.116","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2020092107450524000_370.sep21_2.m3176.117","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S150524"},{"key":"2020092107450524000_370.sep21_2.m3176.118","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.11.002"},{"key":"2020092107450524000_370.sep21_2.m3176.119","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"2020092107450524000_370.sep21_2.m3176.120","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2595"},{"key":"2020092107450524000_370.sep21_2.m3176.121","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002509"},{"key":"2020092107450524000_370.sep21_2.m3176.122","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756"},{"key":"2020092107450524000_370.sep21_2.m3176.123","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2020092107450524000_370.sep21_2.m3176.124","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-741058"},{"key":"2020092107450524000_370.sep21_2.m3176.125","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000068"},{"key":"2020092107450524000_370.sep21_2.m3176.126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"2020092107450524000_370.sep21_2.m3176.127","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.388"},{"key":"2020092107450524000_370.sep21_2.m3176.128","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128528"},{"key":"2020092107450524000_370.sep21_2.m3176.129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.002"},{"key":"2020092107450524000_370.sep21_2.m3176.130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088"},{"key":"2020092107450524000_370.sep21_2.m3176.131","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14145"},{"key":"2020092107450524000_370.sep21_2.m3176.132","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X"},{"key":"2020092107450524000_370.sep21_2.m3176.133","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0196-6"},{"key":"2020092107450524000_370.sep21_2.m3176.134","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0178-8"},{"key":"2020092107450524000_370.sep21_2.m3176.135","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0087"},{"key":"2020092107450524000_370.sep21_2.m3176.136","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.3601"},{"key":"2020092107450524000_370.sep21_2.m3176.137","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_200867"},{"key":"2020092107450524000_370.sep21_2.m3176.138","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5600-x"},{"key":"2020092107450524000_370.sep21_2.m3176.139","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123465"},{"key":"2020092107450524000_370.sep21_2.m3176.140","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8055"},{"key":"2020092107450524000_370.sep21_2.m3176.141","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126378"},{"key":"2020092107450524000_370.sep21_2.m3176.142","first-page":"3110","article-title":"Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): updated results from an open-label, phase 1b study","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"2020092107450524000_370.sep21_2.m3176.143","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8055"},{"key":"2020092107450524000_370.sep21_2.m3176.144","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8056"},{"key":"2020092107450524000_370.sep21_2.m3176.145","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128007"},{"key":"2020092107450524000_370.sep21_2.m3176.146","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-153"},{"key":"2020092107450524000_370.sep21_2.m3176.147","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111729"},{"key":"2020092107450524000_370.sep21_2.m3176.148","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.137620"},{"key":"2020092107450524000_370.sep21_2.m3176.149","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.04.024"},{"key":"2020092107450524000_370.sep21_2.m3176.150","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"2020092107450524000_370.sep21_2.m3176.151","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778423"},{"key":"2020092107450524000_370.sep21_2.m3176.152","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-781351"},{"key":"2020092107450524000_370.sep21_2.m3176.153","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126145"},{"key":"2020092107450524000_370.sep21_2.m3176.154","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126689"},{"key":"2020092107450524000_370.sep21_2.m3176.155","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.302"},{"key":"2020092107450524000_370.sep21_2.m3176.156","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30115-2"},{"key":"2020092107450524000_370.sep21_2.m3176.157","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129562"},{"key":"2020092107450524000_370.sep21_2.m3176.158","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111576"},{"key":"2020092107450524000_370.sep21_2.m3176.159","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117729"},{"key":"2020092107450524000_370.sep21_2.m3176.160","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.95103"},{"key":"2020092107450524000_370.sep21_2.m3176.161","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116953"},{"key":"2020092107450524000_370.sep21_2.m3176.162","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0344"},{"key":"2020092107450524000_370.sep21_2.m3176.163","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124298"},{"key":"2020092107450524000_370.sep21_2.m3176.164","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119514"},{"key":"2020092107450524000_370.sep21_2.m3176.165","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050"},{"key":"2020092107450524000_370.sep21_2.m3176.166","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129405"},{"key":"2020092107450524000_370.sep21_2.m3176.167","doi-asserted-by":"publisher","DOI":"10.1042\/BST20150291"},{"key":"2020092107450524000_370.sep21_2.m3176.168","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117737"},{"key":"2020092107450524000_370.sep21_2.m3176.169","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2"},{"key":"2020092107450524000_370.sep21_2.m3176.170","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131839"},{"key":"2020092107450524000_370.sep21_2.m3176.171","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119227"},{"key":"2020092107450524000_370.sep21_2.m3176.172","first-page":"502","article-title":"Universal SLAMF7-specific CAR T-cells as treatment for multiple myeloma","volume":"130","author":"Mathur","year":"2017","journal-title":"Blood"},{"key":"2020092107450524000_370.sep21_2.m3176.173","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607"},{"key":"2020092107450524000_370.sep21_2.m3176.174","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2013.12.001"},{"key":"2020092107450524000_370.sep21_2.m3176.175","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.279"},{"key":"2020092107450524000_370.sep21_2.m3176.176","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000563120.66927.63"},{"key":"2020092107450524000_370.sep21_2.m3176.177","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126818"},{"key":"2020092107450524000_370.sep21_2.m3176.178","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123220"},{"key":"2020092107450524000_370.sep21_2.m3176.179","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121805"},{"key":"2020092107450524000_370.sep21_2.m3176.180","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2752"},{"key":"2020092107450524000_370.sep21_2.m3176.181","first-page":"500","article-title":"Preclinical characterization of AMG 424, a novel humanized T cell-recruiting bispecific anti-CD3\/CD38 antibody","volume":"130","author":"de Zafra","year":"2017","journal-title":"Blood"},{"key":"2020092107450524000_370.sep21_2.m3176.182","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127135"},{"key":"2020092107450524000_370.sep21_2.m3176.183","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127163"},{"key":"2020092107450524000_370.sep21_2.m3176.184","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-785873"},{"key":"2020092107450524000_370.sep21_2.m3176.185","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1703-7"},{"key":"2020092107450524000_370.sep21_2.m3176.186","doi-asserted-by":"publisher","DOI":"10.21037\/sci.2016.11.09"},{"key":"2020092107450524000_370.sep21_2.m3176.187","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.4238.4238"},{"key":"2020092107450524000_370.sep21_2.m3176.188","doi-asserted-by":"crossref","unstructured":"Borrello I Noonan K Ferguson AK . Allogeneic myeloma GVAX with lenalidomide in near complete remission to enhance progression free survival. 2015;33(15_suppl):3082.","DOI":"10.1200\/jco.2015.33.15_suppl.3082"},{"key":"2020092107450524000_370.sep21_2.m3176.189","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21560"},{"key":"2020092107450524000_370.sep21_2.m3176.190","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-277137"},{"key":"2020092107450524000_370.sep21_2.m3176.191","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0282"},{"key":"2020092107450524000_370.sep21_2.m3176.192","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3267"},{"key":"2020092107450524000_370.sep21_2.m3176.193","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2020092107450524000_370.sep21_2.m3176.194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"2020092107450524000_370.sep21_2.m3176.195","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.m3176","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.m3176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:08:28Z","timestamp":1601078908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.m3176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":195,"alternative-id":["10.1136\/bmj.m3176"],"URL":"https:\/\/doi.org\/10.1136\/bmj.m3176","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]}}}